Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q4 FY24 results · Jan–Mar 2024
Alkem Laboratories reported revenue from operations of ₹2,935.82 crore (up 1.1% from Q4 FY23) and net profit of ₹304.48 crore (up 349.9% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,935.82 | 2,902.60 | +1.1% | 3,323.87 | −11.7% |
| Other income | 88.17 | 68.67 | +28.4% | 93.64 | −5.8% |
| Total income | 3,023.99 | 2,971.27 | +1.8% | 3,417.51 | −11.5% |
| Profit before tax | 367.34 | 211.66 | +73.6% | 654.90 | −43.9% |
| Net profit for the period | 304.48 | 67.68 | +349.9% | 604.28 | −49.6% |
| Attributable to shareholders of the company | 293.56 | 70.98 | +313.6% | 594.96 | −50.7% |
| EPS, basic (₹) | 24.55 | 5.94 | +313.5% | 49.76 | −50.7% |
| Net margin (%) | 10.4 | 2.3 | 18.2 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,365.37 | 2,237.99 | +5.7% | 2,494.59 | −5.2% |
| Other income | 83.79 | 76.60 | +9.4% | 95.66 | −12.4% |
| Total income | 2,449.16 | 2,314.59 | +5.8% | 2,590.25 | −5.4% |
| Profit before tax | 389.01 | 329.69 | +18.0% | 534.38 | −27.2% |
| Net profit for the period | 324.97 | 254.79 | +27.5% | 504.23 | −35.6% |
| EPS, basic (₹) | 27.18 | 21.31 | +27.5% | 42.17 | −35.5% |
| Net margin (%) | 13.7 | 11.4 | 20.2 |
Consolidated
- Filed with BSE
- 01 Jun 2024, 11:10 IST
- Board meeting
- 29 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Jun 2024, 11:10 IST
- Board meeting
- 29 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE